Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
"H" stands for "high metal" because CH chondrites may contain up to as much as 40% of metal. That makes them one of the most metal-rich of any of the chondrite groups, second only to the CB chondrites and some ungrouped chondrites such as NWA 12273. The first meteorite discovered was ALH 85085. Chemically, these chondrites are closely related to CR and CB groups. All specimens of this group belong only to petrologic types 2 or 3.
Bryant Park was initially supposed to reopen in late 1990 or early 1991. The reopening date was pushed back due to delays caused by the construction of the library's stacks. In June 1991, the city and BPRC reached an agreement to reopen the western section of Bryant Park on summer weekdays. The park was soft reopened on April 21, 1992, with the official reopening set for nearly a month later. The new design received widespread acclaim. Deemed "a triumph for many" by New York Times architectural critic Paul Goldberger, the renovation was lauded not only for its architectural excellence, but also for adhering to Whyte's vision. According to Goldberger, Biederman "understood that the problem of Bryant Park was its perception as an enclosure cut off from the city; he knew that, paradoxically, people feel safer when not cut off from the city, and that they feel safer in the kind of public space they think they have some control over." The renovation was lauded as "The Best Example of Urban Renewal" by New York magazine, and was described by Time as a "small miracle". Many awards followed, including a Design Merit Award from Landscape Architecture Magazine, and the 1996 Award for Excellence from the Urban Land Institute (ULI). The park has been extolled for its relative calmness and cleanness. Through the 21st century, Bryant Park remained a model of civic renewal that mayors of other cities, such as Jorge Elorza of Providence, Rhode Island, sometimes held up as a model to emulate. Bryant Park was described in the media as an example of New York City's 1990s revival.
== Biography == Palmer was born in Port of Spain on the twin island Republic of Trinidad and Tobago. He is fluent in English and became a U.S. citizen. Palmer earned a chemical engineering degree at Howard University in Washington D.C in 1993 and his doctorate in chemical and biomolecular engineering at Johns Hopkins University in 1998. After completing postdoctoral work at Johns Hopkins University in 1999, Palmer joined the Chemistry Department faculty at Howard University. In 2001, he left for the University of Notre Dame to become assistant professor of chemical and biomolecular engineering. In 2006, after five years, he moved to Ohio State University to become associate professor of chemical and biomolecular engineering, and was promoted to full professor in 2012. He served as interim department chair in 2014–2015. In 2015, he was named Chair of the William G. Lowrie Department of Chemical and Biomolecular Engineering and served until 2019. In March 2020, the Ohio Board of Regents named Palmer, "Ohio Eminent Scholar," a statewide endowed chair. In August 2021, Palmer was appointed Associate Dean for research, charged with directing the College of Engineering's $138 million research enterprise.
Sources: en.wikipedia.org
Chem. Int. Ed. 2017, 56, 16018-16022. https://doi.org/10.1002/anie.201709463. M, Hifsudheen.; R, K, Mishra.; B, Vedhanarayanan.; V, K, Praveen.; and Ajayaghosh, Ayyappanpillai (2017). “Helix to Super-Helix Transition in p-Systems Self-assembly: Superseding of Molecular Chirality at Hierarchical Level”. Angew. Chem., Int. Ed. 2017, 56, 12634-12638. https://doi.org/10.1002/anie.201707392. S, Ghosh.; S, Cherumukkil.; C, H, Suresh.; and Ajayaghosh, Ayyappanpillai (2017). “A Supramolecular Nanocomposite as Near Infrared Transmitting Optical Filter for Security and Forensic Applications”. Adv. Mater. 2017, 29, 1703783.doi:10.1002/adma.201703783 A, Mal.; R, K, Mishra.; V, K, Praveen.; M, A, Khayum.; R, Banerjee.; and Ajayaghosh, Ayyappanpillai (2018). “Supramolecular Reassembly of Self-Exfoliated Ionic Covalent Organic Nanosheets for Label-Free Detection of dsDNA”. Angew. Chem., Int. Ed. 2018, 57, 8443. https://doi.org/10.1002/anie.201801352. R, D, Mukhopadhyay.; G, Das.; and Ajayaghosh, Ayyappanpillai (2018). “Stepwise Control of Host-Guest Interaction Using a Coordination Polymer Gel”. Nat. Commun. 2018, 9, 1987. https://doi.org/10.1038/s41467-018-04303-8. V, K, Praveen.; B, Vedhanarayanan.; A, Mal.; R, K, Mishra.; and Ajayaghosh Ayyappanpillai (2020). “Self-Assembled Extended p‑Systems for Sensing and Security Applications”. Acc. Chem. Res. 2020, 53, 2, 496-507. https://doi.org/10.1021/acs.accounts.9b00580 S, Chakraborty.; M, M, Joseph.; S, Varughese.; S, Ghosh.; K, K, Maiti.; A, Samanta.; and Ajayaghosh, Ayyappanpillai (2020).
== Chemistry == Mitragynine pseudoindoxyl was first accessible via biomimetic semisynthesis from mitragynine. Total synthesis of an unnatural analogue was reported featuring an interrupted Ugi reaction as the key step. Scalable and modular total synthesis of the natural product has also been accomplished using a chiral pool based strategy. This study also demonstrated structural plasticity in biological systems.
=== Europe === Dihydromorphine is regulated in the same fashion as morphine in Germany under the BtMG, Austrian SMG, and Swiss BtMG, where it is still used as an analgesic. The drug was invented in Germany in 1900 and marketed shortly thereafter. It is often used in Patient Controlled Analgesia units.
Sources: en.wikipedia.org
== Society and culture == The American TV show, Diagnosis, in episode 1 Detective Work, an athletic 23-year-old nursing student, Angel Parker, experiences episodes of extreme muscle fatigue, pain and cramping after prolonged exercise, sometimes followed by dark urine (myoglobinuria) and elevated CK (rhabdomyolysis). These episodes can leave her immobile for hours. She had experienced muscle pains since childhood, passed-off as "growing pains." Her first hospitalization was at age 14, for intolerable leg pain that woke her in the middle of the night, sobbing uncontrollably from the intense pain. After multiple hospitalizations for myoglobinuria and rhabdomyolysis, many misdiagnoses, and many different doctors and tests that were unable to give an explanation for her symptoms, through the assistance of the show genetic sequencing confirmed that she had CPT-II deficiency (a fatty-acid metabolism disorder). In 2010, Walk over Wales (WoW), the first walking course for those with muscle glycogen storage disease occurred to teach participants activity adaptations, swap notes, and raise public awareness. Led by Andrew Wakelin, participants came from around the world, including Stacey Reason, Dan Chambers, Andy Williams, Charlton Thear and Dr. Ros Quinlivan. From Great Orme to Cardiff Bay, in 32 days they walked 210 miles (338 km) and ascended approximately 35,000 feet (10,700 metres) through Snowdonia National Park, the Cambrian Mountains, and Brecon Beacons National Park.
He ruled that only Whitehall could determine what constituted the maintenance of "law and order" in Rhodesia, and that the Rhodesian emergency measures were unlawful as they had been formalised by the Officer Administering the Government, a post-UDI figure who was, in British eyes, unconstitutional. Reid concluded that Madzimbamuto was illegally detained. Harry Davies, one of the Rhodesian judges, announced on 8 August that the Rhodesian courts would not consider this ruling binding as they no longer accepted the Privy Council as part of the Rhodesian judicial hierarchy. Justice J. R. Dendy Young resigned in protest at Davies' ruling on 12 August and four days later was sworn in as Chief Justice of Botswana. The Rhodesian High Court granted full de jure recognition to the post-UDI government on 13 September 1968, while rejecting the appeals of 32 black Rhodesians who had been a month earlier convicted of terrorist offences and sentenced to death. Beadle declared that while he believed the Rhodesian judiciary should respect rulings of the Privy Council "so far as possible", the judgement of 23 July had made it legally impossible for Rhodesian judges to continue under the 1961 constitution. He asserted that the court therefore faced a choice between the 1965 constitution and a legal vacuum, the latter of which he felt he could not endorse.
== Treatment == Medical treatment has not proven consistently effective. Medical regimens have included tamoxifen, progesterone, bromocriptine, the gonadotropin-releasing hormone agonist leuprorelin, and testosterone. Gestational macromastia has been treated with breast reduction drugs alone without surgery. Surgical therapy includes reduction mammaplasty and mastectomy. However, breast reduction is not clinically indicated unless at least 1.8 kilograms (4.0 lb) of tissue per breast needs to be removed. In the majority of cases of macromastia, surgery is medically unnecessary, depending on body height. Topical treatment includes regimens of ice to cool the breasts. Treatment of hyperprolactinemia-associated macromastia with D2 receptor agonists such as bromocriptine and cabergoline has been found to be effective in some, but not all cases. Danazol, an antiestrogen and weak androgen, has also been found to be effective in the treatment of macromastia. When hypertrophy occurs in adolescence, noninvasive treatments, including pharmaceutical treatment, hormone therapy, and steroid use are not usually recommended due to known and unknown side effects. Once breast growth rate has stabilized, breast reduction may be an appropriate choice. In some instances after aggressive or surgical treatment, the breast may continue to grow or re-grow, a complete mastectomy may be recommended as a last resort. Pregnancy is recognized as the second most common reason for hypertrophy. When secondary to pregnancy, it may resolve itself without treatment after the pregnancy ends.
Compared to traditional cigarettes, reusable e-cigarettes do not create waste and potential litter from every use in the form of discarded cigarette butts. Traditional cigarettes tend to end up in the ocean where they cause pollution, though once discarded they undergo biodegradation and photodegradation. A 2025 review in Nicotine & Tobacco Research concluded that the chemical, metallic and electrical composition of e-cigarettes could qualify them as hazardous and electronic waste, and recommended clear, enforceable disposal and recycling requirements, including manufacturer responsibility and consumer-facing recycling information, in jurisdictions where e-cigarettes are legally sold. E-cigarettes that are not reusable contribute to the problem of electronic waste, which can create a hazard for people and other organisms. If improperly disposed of, they can release heavy metals, nicotine, and other chemicals from batteries and unused e-liquid. A 2024 open-access study in Science of the Total Environment that dismantled nine popular disposable vapes reported a complex mix of plastics and metals, including toxic or potentially toxic elements such as lead and mercury, which the authors noted could pose environmental hazards through leaching after littering or landfilling. A July 2018–April 2019 garbology study found e-cigarette products composed 19% of the waste from all traditional and electronic tobacco and cannabis products collected at 12 public high schools in Northern California.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.